Troubles Brought by Fame

"Chinese Scientists Unravel Virus Evolution Patterns, Providing New Ideas for Broad-Spectrum Vaccine Design"

"Chinese Scientists Propose Broad-Spectrum Vaccine Design Strategy to Combat Continuous Viral Mutation"

"A Glimmer of Hope for Complete Eradication of the Virus, Research Results by Chinese Scientists Help End the Global Pandemic!"

Starting from a certain year, domestic media in China completely lost their function of news reporting. For newsworthy events, they either waited for official announcements or reprinted foreign news. The depth and breadth of their news coverage were inferior to self-media.

It wasn't even "inferior," it was simply worse than many self-media outlets that reported facts truthfully.

While Chinese media copied reports from overseas media, Chinese self-media outlets clearly analyzed Chen Yuanguang's past glorious history, his current research achievements, and the positive significance of these achievements for ending the viral pandemic.

"The hottest topic in overseas media recently is the paper published by a Chinese scientist in Science, which is expected to end the global viral pandemic ahead of schedule in the short term.

What exactly is going on? Simply put, this Chinese scientist used simulation calculations to calculate the future mutation paths of the virus and accurately predict the mutation sites of future viral variations.

This way, pharmaceutical institutions can get the mutation sites of viral variations in advance and design vaccines that cover both current and future viral mutation sites. This means you don't have to worry about immune escape with the vaccine you receive.

Previously, even mRNA vaccines were only effective for half a year or even less, but with broad-spectrum vaccines, they can be effective for three years or even longer.

Therefore, the media are saying that the global pandemic of the virus is expected to end ahead of schedule.

I see that many viewers have sent me private messages with questions in the backend. I'll pick some typical ones to answer.

Is this a breakthrough achievement? Absolutely. His paper has data verifying that his simulation algorithm is correct, and new data will verify his algorithm in the future. This is a major breakthrough in the field of virology using biological computation.

Considering the historical context, its significance is even greater.

Can this research achievement help end the global viral pandemic? It has a very positive effect, but whether it can completely end it, I can't say for sure.

Because vaccine research and development costs money, production costs money, and transportation costs money. Broad-spectrum vaccines will be even more expensive than regular mRNA vaccines. Developed countries can afford to inject them, but underdeveloped regions like Africa and the Middle East clearly don't have the money. What if a 'Gu King' (Gu King - a term referring to a highly mutated and resistant virus) emerges there?

Completely ending it, I don't know, and I can't say for sure.

Who is the author, so amazing? Oh, I forgot to mention, many viewers should have heard of him. Chen Yuanguang, the author of the original novel 'Kuala Lumpur Affairs', just graduated from Jiang University last year and went to MIT. He published two Nature papers while at Jiang University, and another Nature paper after going to MIT. This should be considered his fourth top-tier publication. He is definitely a genius young man.

All his previous top-tier publications were focused on the field of simulation calculation, so there isn't much skepticism from the academic community about his new achievement this time. His papers are all applications of simulation calculation in chemistry, biology, and virology, which is within his area of expertise.

It's just that this time, his achievement has made us realize once again how much impact the combination of deep learning algorithms and biological computation can have. I estimate that the field of biological computation will be packed in the next few years.

Will he return to China or stay in America? How would I know? I don't know him. I'll ask my friends at Jiang University if they know him, and then I'll ask my friend to ask him.

He hasn't even graduated with his doctorate yet. With so many top-tier achievements, it's easy for him to get a professorship at MIT. Why would he come back to China to compete? Isn't there a joke that even Hawking would have to toast when he comes to China?

But it's not necessarily the case. This kind of top talent is on a different track from us. They don't need to compete when they come back; they can easily get professorships and titles. It just depends on himself.

Can this achievement win a Nobel Prize? I can only say there is hope, but he is too young. I don't think they will give it to him so quickly. The Nobel Prize committee will definitely wait a few years before giving it to him.

But he is definitely the most promising candidate in China to win the award. Chen Yuanguang's achievements in the fields of biological computation and computational chemistry are among the best. It's no exaggeration to say he is a leader in these fields, and he is too young, only in his early twenties. There is great hope for him to win the award later.

I can only say that at the same age, in my early twenties, I'm still worried about graduating with my doctorate and making a living by posting videos on Bilibili as an internet celebrity. Damn, why does it get sadder the more I talk about it?" A video by a Bilibili uploader was much more detailed than the reports from Chinese media.

Chen Yuanguang's achievement sparked heated discussions globally, and large pharmaceutical groups quickly began the research and development of broad-spectrum vaccines.

Everyone knows that compared to the latest broad-spectrum vaccines, mRNA is no longer popular. Broad-spectrum vaccines are the future.

"Pangalos, how was the communication with Light Chen?

Did he accept our offer?" Dobert asked. He is the Executive Vice President and President of the Biopharmaceuticals Business Unit at AstraZeneca.

Pangalos shook his head, "Chen firmly rejected our invitation. He probably still wants to stay in academia.

I think we need to change our approach to cooperating with Chen. For top scientists like him, they always prefer to stay in the ivory tower rather than join the industry in the early stages of their careers.

I thought about it later, and we can definitely cooperate. We can hire him as a special consultant, and his future results on the simulated evolution of the COVID virus will only be shared with AstraZeneca and not published.

In this way, our vaccine will have a longer validity period, which will be our exclusive advantage. With AstraZeneca's advantage in Europe, European governments will only consider AstraZeneca, and we will monopolize the entire European market.

Even if Pfizer asks the Americans to coordinate, we can use this advantage to leave the American side speechless."

Dobert thought it was a good idea, but he had a big question mark about whether the EU could refuse the American demands.

Even if their vaccine was far ahead of Pfizer's, the EU government would still have to give Pfizer a certain share.

But that wasn't important. Even if it was just the majority share, it would be enough for AstraZeneca to present a stunning report card to the board this year, and they, as executives, would also receive substantial bonuses.

It wasn't just AstraZeneca that thought of this; institutions like Pfizer and Merck also thought of it.

Chen Yuanguang was so bothered that he decided to cut the Gordian knot quickly. He sent a mass message on WhatsApp directly: I will no longer do simulations in this area. I will switch to other research directions in the future. Then he turned off his phone directly.

Why did he choose this? Because the compensation for being a special consultant for these pharmaceutical companies and keeping papers confidential wasn't much. As a bestselling author and IP owner, he earned much more than that.

His simulation method had already been published, and these pharmaceutical companies could also get a rough result by following the example. Therefore, they were unwilling to offer a high price, and the price they offered was very limited.